MedMira获得新型诊断技术平台

 
 
一种新型生物传感器技术平台允许操作者迅速而有效地评估多种诊断指标，简化了患者床边检测的时间。

这种平台叫做Project Maple，是由加拿大多伦多大学的一一个研究小组发明的，由化学系分析化学教授和生物物质与生物化学工程研究所副研究员Michael Thompson博士主持的。

这个平台属于Sensor Chem International集团，现在被MedMira公司(Halifax, Canada; www.medmira.com)获得，该公司计划使用这种新技术来扩大产品线。这种来自Project Maple的新产品和应用软件将会成为MedMirwa产品线的补充，包括HIV、丙型肝炎和其它感染性疾病的床边检测。根据MedMira的说法，这种新技术能够很方便地用于诊所、医院和实验室。

面对实验室困难和对更加快速、可靠检测结果地需求，临床实验室一直致力于自动而简便的检测。Project Maple产品线能够确保快速和简便的样本处理，以及将数字诊断结果整合进入电子患者病例记录系统。

MedMira将会为购买SensorChem支付大约2,066,720美元。SensorChem将会继续作为MedMira完全拥有的分支结构。MedMira为全球的健康保健结构提供快速诊断解决方案。

New Diagnostic Technology Platform
 
A new biosensor technology platform allows users to assess multiple diagnostic markers quickly and efficiently, facilitating a fast turnaround time in patient point-of-care (POC) testing.

The platform, known as Project Maple, was invented by a team of researchers at the University of Toronto (Canada), headed by Dr. Michael Thompson, professor of analytic chemistry in the department of chemistry and associated member of the Institute for Biomaterials and Biomedical Engineering. The platform, owned by Sensor Chem International Corp., is being acquired by MedMira, Inc. (Halifax, Canada; www.medmira.com), which plans to use the new technology to broaden its product offerings.

The new products and applications resulting from Project Maple will complement the current product portfolio of MedMirwa, which consists of rapid flow-through POC tests for HIV, hepatitis C, and other infectious diseases. The new technology can be easily implemented in clinics, hospitals, and laboratories, according to MedMira.

Facing labor shortages and demand for faster, reliable test results, clinical laboratories are continually looking for increased automation and simplicity.

Project Maple’s product line will enable fast and easy sample preparation and the ability to provide digital tracking of diagnostic results into electronic

patient record systems.

MedMira will buy all the outstanding chares of SensorChem for about U.S.$2,066,720. SensorChem will continue to operate as a wholly owned subsidiary of

MedMira. MedMira supplies rapid diagnostic solutions to healthcare communities around the world.